Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's the seceret formula? Why do you need to create your own board? What are the criteria for stocks here? Your RB history is less than six months and relatively limited....that's not a very convincing track record....why should I believe you?
Are you a prophet or is this a cult?
This looks alright to me?
Dear Stockholder:
We are writing to you today to request your authorization to make a portion of
our authorized and unissued Biophan shares preferred, to facilitate a potential
transaction between Biophan and a large biomedical device company. The
transaction with this potential strategic partner, which is in an advanced stage
of negotiation, may include license fees, milestone payments, and royalties, on
several product lines already in the market, with sizeable upside potential for
us. Part of the package being discussed involves an equity investment,
potentially at a premium over market, which will provide us an alternative to
the current financing package that we have available.
We have been informed by the prospective partner that any investment that it may
make must be in preferred stock. As you know, this gives a preference in the
event of a sale or liquidation. While the terms of the preferred stock will be
fixed in the future, we expect any preferred stock issued in the currently
contemplated transaction to be identical to common stock except for the
liquidation preference (i.e., it will have no special voting rights, etc.). At
the recent Biophan annual meeting the stockholders approved additional shares to
allow us to achieve corporate purposes including taking all or part of the SBI
financing, and/or a strategic investment. The shares already registered for
potential sale to SBI cannot be used for a sale to the strategic partner.
What we are seeking is your approval for us to substitute shares of preferred
stock for a portion of the shares of common stock that were authorized at the
annual meeting. We do not anticipate needing more than about 10 million shares
of preferred stock for the potential transaction currently being considered, but
to be safe, and because there is interest from other large companies, we are
requesting that you authorize up to 15 million of the CURRENTLY AUTHORIZED
shares to be authorized as preferred shares to provide the Board with
flexibility as it seeks to effect strategic transactions.
By getting your approval now, in advance, we can avoid the delays and
uncertainty associated with requiring a stockholders meeting at the time we want
to enter into a strategic transaction. If the potential transaction that is
currently contemplated does not occur, the preferred shares will be available
for similar transactions that may occur in the future.
Our recent announcement of the joint agreement with NASA on the biothermal
battery, our achieving a total of 80 patents issued, pending or licensed in, and
most importantly, the potential transaction being negotiated about which we are
writing to you, are exciting developments in our business.
-2-
It is only with your continued, ongoing support that we have been able to make
this progress, and on behalf of our employees, board members, and future
customers, we thank you again.
Enclosed with this letter is a notice of a stockholders meeting and a proxy
statement describing in more detail the proposed authorization of preferred
stock. Please vote in the affirmative on the enclosed proxy card and return it
in the prepaid envelope.
Sincerely,
Michael L. Weiner
Chief Executive Officer
Guenter H. Jaensch
Chairman of the Board
It's a nice gesture to reduce the number of authorized common shares appropriately....many penny stocks would not have worried about that. As long as this deal includes the financial commitments (license fees, milestone payments, and royalties) to make sure this partner doesn't have the incentive to drive Biophan into bankruptcy to collect the intellectual property.....this seams alright. But now we pretty well know we have to wait another 2 months for good news....wish they had figured this out before the meeting this summer?
BIPH...Catfish...Gary...anyone have an opinion on this:
http://www.sec.gov/Archives/edgar/data/1084000/000114420404014626/v06809_pre14c.txt
October______, 2004
Dear Stockholder:
We are writing to you today to request your authorization to make a portion of
our authorized and unissued Biophan shares preferred, to facilitate a potential
transaction between Biophan and a large biomedical device company. The
transaction with this potential strategic partner, which is in an advanced stage
of negotiation, may include license fees, milestone payments, and royalties, on
several product lines already in the market, with sizeable upside potential for
us. Part of the package being discussed involves an equity investment,
potentially at a premium over market, which will provide us an alternative to
the current financing package that we have available.
We have been informed by the prospective partner that any investment that it may
make must be in preferred stock. As you know, this gives a preference in the
event of a sale or liquidation. While the terms of the preferred stock will be
fixed in the future, we expect any preferred stock issued in the currently
contemplated transaction to be identical to common stock except for the
liquidation preference (i.e., it will have no special voting rights, etc.). At
the recent Biophan annual meeting the stockholders approved additional shares to
allow us to achieve corporate purposes including taking all or part of the SBI
financing, and/or a strategic investment. The shares already registered for
potential sale to SBI cannot be used for a sale to the strategic partner.
What we are seeking is your approval for us to substitute shares of preferred
stock for a portion of the shares of common stock that were authorized at the
annual meeting. We do not anticipate needing more than about 10 million shares
of preferred stock for the potential transaction currently being considered, but
to be safe, and because there is interest from other large companies, we are
requesting that you authorize up to 15 million of the CURRENTLY AUTHORIZED
shares to be authorized as preferred shares to provide the Board with
flexibility as it seeks to effect strategic transactions.
By getting your approval now, in advance, we can avoid the delays and
uncertainty associated with requiring a stockholders meeting at the time we want
to enter into a strategic transaction. If the potential transaction that is
currently contemplated does not occur, the preferred shares will be available
for similar transactions that may occur in the future.
Our recent announcement of the joint agreement with NASA on the biothermal
battery, our achieving a total of 80 patents issued, pending or licensed in, and
most importantly, the potential transaction being negotiated about which we are
writing to you, are exciting developments in our business.
<PAGE>
-2-
It is only with your continued, ongoing support that we have been able to make
this progress, and on behalf of our employees, board members, and future
customers, we thank you again.
Enclosed with this letter is a notice of a stockholders meeting and a proxy
statement describing in more detail the proposed authorization of preferred
stock. Please vote in the affirmative on the enclosed proxy card and return it
in the prepaid envelope.
Sincerely,
Michael L. Weiner
Chief Executive Officer
Guenter H. Jaensch
Chairman of the Board
Who is this Johny come lately? Before we get carried away with all this speculation of his hiring being a contingency of an agreement with BSX, let's first look to see who he really is and what he's really worth?
Here's the best personal profile I could find:
http://www.hexagon.dk/pages/Conferences/Conferences%202003/MP%202003/Speakers/Lanzafame_John.htm
He was the President of STS for about a year:
http://www.stsbiopolymers.com/CompanyNews/PressReleases/prnewpresident9-4-03.htm
Looks like this guy has a patent for coating needles to be visible under ultrasound:
http://www.devicelink.com/expo/awards02/stsbiopolymers.html
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=/netahtml/search-adv.htm...
I imagine he left that patent at Angiotech?
He keeps coming up on this search, but I can't find any specific mention of him in here:
http://www.uspto.gov/web/patents/patog/week34/OG/patentee/alphaL_Utility.htm
He also showed up on references to STS opposing Angiotech patent awards......maybe Angiotech just snatched-up STS to shut this guy up?
He looks like a good asset, Biophan should know, they've given him a three month test drive. I know he sure can do some neat stuff with power point presentations!
I've been spotting more of good opportunites lately, but I'm a little trigger shy in this market still.
ANTR has put on about a 30% gain since I mentioned it a few weeks ago, but I never pulled the trigger.
DSNY looked cheap a few days ago...and still looks pretty cheap now....but I haven't bought yet.
Now with LENF today, the company has proven they make sales and turn a profit with their other products, but I'm not sure the market is convinced of their abilites....and I think there could be better entry points ahead before these stun guns get to market? Since I've said this, it's bound to go to $3.00 without ever looking back :)
BIPH investors, here's some good news, MRI-safety is getting the attention of the FDA:
http://newsobserver.com/news/story/1628887p-7845995c.html
Published: Sep 12, 2004
Modified: Sep 12, 2004 4:35 AM
MRI tests focus on implants
By LAURAN NEERGAARD, The Associated Press
WASHINGTON -- A mannequin skull sits in an MRI machine, about to be filled with a thick, brain-like gel.
MRIs -- short for magnetic resonance imaging -- are required tests for numerous disorders. But MRIs are off-limits for millions of patients with certain implants, such as pacemakers or brain electrodes. The scanners can dangerously heat the metal parts.
"The MRI industry thinks it's simple: 'Don't use' " in those patients, said the Food and Drug Administration's Larry Kessler. "That's not the end game."
Instead, amid pressure from doctors, the agency wants to speed development of MRI-compatible implants.
Hence the mannequin, part of a little-known FDA research program in which 140 scientists probe the pitfalls and promises of medical devices.
Much of the work by Kessler's $21 million Office of Science and Engineering Laboratories is aimed at helping the FDA better analyze new devices before approving their sale.
Because problems frequently arise later, these scientists also are giving scrutiny to the usefulness of equipment already on the market -- and whether they can spur improvements.
Consider the MRI dilemma.
Recently, a man was left temporarily comatose after an MRI scan was performed even though he had a "deep brain stimulator," an implant increasingly used to fight Parkinson's disease and other tremors. Two other brain-stimulator recipients died, not after MRIs but after a heat therapy called diathermy that emits the same radio-frequency energy as MRIs do.
The FDA is trying to find ways to make MRIs safe for people with these and other implants.
FDA scientist Howard Bassen filled the mannequin skull with a gel substance similar to the consistency of the brain. He attached electrodes from a deep brain stimulator and zapped the skull with the radio waves that MRIs and diathermy emit.
The electrodes' temperature rose more than 20 degrees in 5 seconds, Bassen found. Heat concentrated at the tip where it can burn a hole in delicate brain tissue. The thinner the wire, the hotter it got; that is important for recognizing which devices are riskier.
Manufacturers are working to create MRI-compatible implants. Doctors are looking for ways that recipients of older implants can get scanned safely. Models such as Bassen's mannequin should help those attempts, Kessler said.
Stuki, here's the most encouraging comment about EZEN's "Harry B. Heisler" that I found. As I searched the internet I was very encouraged to see this guys name all over Micron and GTSI press releases about government procurement, but the following comment at Amtower and Company "Your online Government marketing Resource" was cetainly the most encouraging:
http://www.federaldirect.net/offwhite23.html
"I do not have a crystal ball, but I have been studying this market for years. I do not know what is going to happen, but here is my best shot.
My friend, Harry B Heisler, will land somewhere and make a big difference. Harry was at GTSI for a decade in the early years, as was Alan Bechara. Harry is responsible for the growth MPC experienced in this market. And he is currently an unused senior resource. As this is VAR Wars, think “Obie Wan.”
ANTR: Heavy volume in ANTR Friday. Insiders were buying all week. I'm not in yet, but looks like a situation worth watching at least.
OT: Catfish
I undertand your point....overloading is very stressful. I have overloaded on quite a few stocks with mixed results, fortunately more possitive than negative lately. I was overloaded on BIPH @ $0.40 last year. Overloaded on BOCX in April of this year right before the run (thanks to you). Overloaded on SEHO and SSPI for their runs too.
As a small fish I need to overload to keep in the game. My total portfolio is probably a fraction of some of your smaller positions. I've already withdrawn more from my portfolio this year than I had at the begining of the year....and that is just to keep up with my living expenses....luckily I'm up more than 250% this year.
Because the market has been tough lately, I'm begining to look for work again. But thanks to the help from you, Gary, and others...this stint of unemployment hasn't been nearly as painful as it could have been.
I intend to stay in this game, but some earned income would help my stuation at this point.
Back to writing resumes.
ADGO: I called IR and left an annimate complaint about the lack of news and the fact the Chairman is selling. The least they could do is issue a PR about earnings to increase liquidity for the chairman to sell into!
He's sold 256,500 of his 340,000 he registered to sell in June....so I hope he's done soon. I continue to hold because of value, but am very disapointed that the chairman would sell so cheap. My only hope is that maybe he's deliberately selling these during this low-liquidity to deliver them to institutional shareholders that will support a move higher in this stock eventually? Maybe...I hope? I'll wait and see if institutional ownership has increased since last quarter.
EZEN: I googled this "Harry B. Heisler" and came up with numerous hits from gov't procurement sites. This guy is a heavy hitter....and has several key contacts within the gov't.
When I was working for the DOE in Nevada I wondered why the offices were full of Micron PCs......now I know why....Henry Heisler is a heck of a salesman. Quite an asset for our little EZEN!
PHPG:
I like PHPG more than STKR because PHPG is 1/3 the market cap of of STKR and I think Northrop has a better chance than BAE at being selected for this work. Not to mention, this quote from a PHPG press release:
"INRAD has been the sole supplier of these elements for the present generation of systems for slow-flying aircraft, and had previously produced many thousands for the prior generation of systems."
It came from this press release:
http://www(dot)ppgrpinc(dot)com/pdfs/AlliantProductionMarch2004.pdf
BIPH - They should be getting closer to striking a licensing deal with Boston Scientific. The CEO has also said in recent interviews they're getting closer to striking an equity investment deal with one of their partners to replace the SBI financing that was announced this spring. During the annual shareholder meeting the CEO said that the first tranche of the SBI financing was in process, but that they are being judicious while waiting to strike an equity deal with a strategic partner.
Considering the SBI financing was at an average of $1.41/share, hopefully they can reel in a partner for similar or better terms, despite the current PPS?
There's not many OTC CEOs that I trust, but Mike Weiner is proving himself to be a man of his word.
BIPH:
Here's a study from John Hopkins (sponsored by Medtronic, St. Jude, and Guidant) that might be resposible for the lower PPS today. The big boys fight back with paid research, but notice they aren't changing their reccomendations to avoid MRI scanning with their products implanted based on this report:
http://scienceblog.com/community/article3477(dot)html
This article contains some comments from Biophan:
democratandchronicle.com/biznews/081022569I2_business.shtml
Biophan gets key patent
Process allows probe devices to be seen during MRI
By Michael Wentzel
Staff Writer
(August 10, 2004) — Biophan Technologies Inc. of Henrietta has added another patent-protected technology to its portfolio that could boost the company's efforts in the medical-device business.
Nanoset, a private company based in East Rochester and a Biophan research partner, has received a patent on a particle-coating technology. Devices, such as biopsy probes and guide wires, currently can not be detected clearly in the body by magnetic resonance imaging. This technology makes the devices visible in an MRI.
Biophan has exclusive worldwide rights to medical uses of the technology, Michael Weiner, Biophan's chief executive officer, said Monday.
The technology will help advance the development of surgery and other procedures guided by medical resonance imaging or MRI, he said.
Shares of Biophan closed Monday at 69 cents, up 4 cents. In the last year, the stock has reached a high of $1.65 and a low of 10 cents.
Weiner also disputed the impact of a new Johns Hopkins University School of Medicine study that found that devices such as pacemakers and defibrillators can be safe for use in magnetic resonance imaging or MRI.
For more than two million Americans who have an implanted device, such as a pacemaker, magnetic resonance imaging is considered unsafe and is rarely used, even though an MRI is the best tool for diagnosing many cancers and some heart conditions.
Biophan is developing technology to make the devices and surgical and diagnostic tools safe and compatible with MRI equipment by reducing heat and filtering distortion.
The Hopkins study, published last week in the journal Circulation, found that an MRI did not cause the metal components in selected devices to heat up enough to damage tissues. The researchers, who conducted tests in animals and in the lab, also said an MRI did not dislodge the device or damage it.
The Food and Drug Administration is well aware of the risks of an MRI for a patient with an implanted device, Weiner said.
“The Hopkins study is important but not exactly accurate,” Weiner said. “The FDA won't approve the use of MRIs until they are made safe and not the way they are made today.”
Dr. Emanuel Kanal, professor of radiology at the University of Pittsburgh Medical Center and chairman of the American College of Radiology's magnetic resonance safety committee, said there is no guaranteed way to make an MRI safe for a patient with an implant.
“A tremendous amount needs to be done before this can be considered safe,” Kanal said. “The Hopkins study is excellent research but it has been blown out of proportion.”
Kanal said Biophan's technology has “tremendous promise” but might not be the method chosen by the medical device industry.
Weiner said the Hopkins study erred in examining only newly-implanted devices. Tissue grows around some pacemaker components after implant. An MRI can heat up the components, causing tissue damage and scarring, according to Biophan studies.
With the addition of the Nanoset patented technology, Biophan can provide a way to see an implanted device or tool and prevent it from heating, Weiner said.
MWENTZEL@DemocratandChronicle.com
Bought some VRDM today. Got a response from IR that the insider purchase was up to $0.65....so $0.21 seamed like a deal.
This pact with Safety-Kleen looks like a good deal too:
Veridium Forms National Pact With Safety-Kleen
Tuesday June 29, 10:49 am ET
Premier Organic and Inorganic Industrial Waste Recyclers Join Forces to Provide Unparalleled Service Options to National Market
PATERSON, N.J., June 29 /PRNewswire-FirstCall/ -- Veridium Corporation ("Veridium") (OTC Bulletin Board: VRDM - News), an environmental services provider that uses its patented and proprietary green technologies to recycle, reuse and mine commodities from industrial hazardous wastes, today announced its execution of a distribution and recycling services agreement with Safety-Kleen Systems, Inc.
ADVERTISEMENT
The agreement calls for most-favored inter-company pricing, mutual rights of first refusal and cooperative marketing, and includes performance-based terms that allow Safety-Kleen to earn price discounts, exclusivity and the right to receive equity in Veridium as they meet and exceed sales benchmarks of up to $50 million in revenue per year. The equity participation terms of the agreement allow Safety-Kleen to earn the right to receive stock options in Veridium exercisable at prices ranging from $0.77 to $5.00 per share into 1.35 million shares of Veridium common stock.
"This alliance is a watershed event in our industry that will have a major impact on the ongoing shift away from consumption to the commoditization of industrial wastes," said Kevin Kreisler, Veridium's chairman and chief executive officer. "More than 95% of the industrial hazardous wastes generated domestically are merely burned or buried. We have the technology today to cost-effectively recycle, reuse and mine a very broad array of these materials. The combination of Veridium's and Safety-Kleen's recycling technologies and Safety-Kleen's national service and distribution assets -- the largest of their kind in North America -- will enable us to provide our clients with services that are unrivaled by any of our competitors."
Powerful Benefits for Industry and the Environment
Industrial hazardous wastes are generated by a vast array of manufacturing processes in many industries including chemicals, ceramics, aerospace, pharmaceuticals, telecommunications, electronics, petrochemicals, automotive, food products, munitions, metal finishing, metals mining and manufacturing, optics and plastics.
Hazardous waste management companies, such as Safety-Kleen and Veridium, are retained by companies in these industries to manage their industrial wastes safely and in compliance with environmental regulations. This service typically takes the form of reverse distribution, where the wastes are picked up at their "cradle" and predominantly distributed to their "grave" -- a disposal or incineration process. Most of these wastes, however, contain valuable metals, chemicals and fuels that can be recovered and returned to the cradle of commerce by using green technologies. This can be achieved today by Safety-Kleen and Veridium at the same cost to the generator as disposal or incineration. Further, recycling hazardous wastes in this manner qualifies generators for powerful exemptions from ongoing environmental liability and state hazardous waste taxes.
"We are at an exciting time and place in our industry," said Fred J. Florjanic, CEO and president of Safety-Kleen, "and we are pleased to have entered into this agreement with Veridium. We believe our combined capabilities give us a competitive advantage, and we are committed to driving revenue growth for both companies."
Safety-Kleen is the premier service provider for recycling organic industrial wastes, such as fuels and solvents, and offers a fully integrated, "one-stop shopping" network designed to collect and process an almost unlimited range of both hazardous and non-hazardous industrial wastes. Safety-Kleen has more than 250 service centers and 5,000 employees across North America, and is the nation's largest re-refiner and recycler of used oil, recovering and re-refining approximately one hundred million gallons of used oil annually.
"We are equally committed to our alliance with Safety-Kleen and look forward to providing our clients with significant added value while we shift Veridium's national development plans into gear," added Jim Green, Veridium's president and chief operating officer. "We intend to construct and operate new recycling facilities in key regions as Safety-Kleen's sales force develops a sufficient core of sales in those regions. We expect in the meantime that Safety-Kleen will be a major source of new revenue and earnings for Veridium."
Kreisler added that "Our combined recycling services are particularly timely given the increasing global demand for metals, chemicals and fuels. Green technologies -- green metals -- green fuels -- green energy -- these are the wave of the future and we look forward with great anticipation to driving the sustainable reuse of our industrial resources into the mainstream as we build the nation's first integrated hazardous waste recycling company."
About Safety-Kleen Systems, Inc.
Safety-Kleen, headquartered in Plano, Texas, is the leading parts cleaner, industrial waste management and oil recycling and re-refining company in North America, with approximately 5,000 employees serving hundreds of thousands of customers in the United States, Canada and Puerto Rico. Safety-Kleen is also proud to be the "Official Environmental and Recycling Service Company" for the NASCAR Nextel Cup, Busch Grand National, Craftsman Truck, IROC, CART and Indy Racing League tracks. Additional information is available online at http://www.safety-kleen.com.
About Veridium Corporation
Founded on the premise that environmentally superior results can be cost-effective, Veridium is setting a new standard for environmental service with its focus on the use of state-of-the-art green technologies to recycle, reuse and mine commodities from industrial hazardous wastes. Veridium's patented and proprietary technologies allow it to offer a uniquely broad array of competitively priced industrial hazardous waste recycling services. Veridium's mission is to minimize and eliminate the need for disposal and reduce the burden on natural resources by recycling, reusing and mining all reusable resources from industrial hazardous wastes in a safe, compliant and profitable manner. Additional information on Veridium and its business model is available online at http://www.veridium.com.
Stuki,
Te market does stink lately, I didn't anticipate this kind og drop in BIPHs PPS, but I do think the R&D with Boston Scientific has been behind these recent developments (i.e.: drug delivery capabilites of BIPH coatings, interventional MRI, etc.). Have you seen the power point presentations from the annual meeting referencing the ability to recharge drug-eluting stents? In my mind, this had to come from the Boston Scientific R&D.....and Boston Scientific is a big enough force in the medical device community to make these things a reality.
Sorry you got in when you did, you're investment could have gone a lot further at these prices, but as these things materialize, I believe BIPH will make much higher highs.
Good luck!
BIPH had great PR this morning. From any other penny stock I might dismiss this as "hype", but BIPH is working with Boston Scientific on their technology.....and Boston Scientific said they're researching and developing many "game changing" technologies in an investor conference earlier this year. This PR sounds like a game changing tech. to me:
Biophan Receives Patent Rights Enabling MRI-Guided Surgery
Monday August 9, 9:29 am ET
Patent Rights Further Expand Biophan's Burgeoning IP Portfolio Supporting Company's Leadership Position in MRI-Safe Technologies
ROCHESTER, N.Y.--(BUSINESS WIRE)--Aug. 9, 2004-- Biophan Technologies, Inc. (OTC BB: BIPH - News), a leading developer of next-generation biomedical technology, announced today that a broad U.S. Patent has been issued to Nanoset, LLC, Biophan's technology partner with Biophan holding the worldwide exclusive rights for all medical applications. The announcement was made by Michael Weiner, Biophan's president and CEO.
ADVERTISEMENT
The Company noted that the nanomagnetic particle coating technology can illuminate devices that are currently difficult to see, either because they are invisible to MRI or because the devices occlude the MRI image. Combined with Biophan's safety solutions, the patented technology is expected to help pave the way to allowing MRI-guided surgical procedures, including minimally invasive procedures such as those used for placing stents, performing RF ablation, angiograms, biopsy probes, and many other procedures.
"Biophan's mission of creating a world-class biomedical patent portfolio is further supported by the addition of these patent rights to our burgeoning portfolio," stated Mr. Weiner. "It provides further evidence of our clear leadership position in developing technologies that make medical devices, such as pacemakers and guidewires, safe for use with MRI. The potential impact of MRI-guided surgery is far reaching and we are pleased to be on the forefront of this revolution."
Mr. Weiner continued, "It is clear that we are meeting our publicly stated objective for further innovation and market expansion. We are pleased to add these patents to our proprietary technology base."
Mr. Weiner went on to note, "Today, most interventional procedures are done under CT scan or fluoroscopy, exposing the patient and physician to ionizing radiation, and providing a less than optimal image of tissue, organs, and vessels. This is done in part because of the problems that have been associated with MRI safety and image problems associated with many medical devices. The significance of this patent is that it teaches how a coating on the device can change the MRI image, reducing the artifacts, and making the invisible devices, such as certain catheters, visible."
Mr. Weiner concluded, "Possibly what is of greatest commercial significance is our expanded dialog with the MRI manufacturers and medical device manufacturers as both groups benefit from seeing this transition to the MRI-guided surgical center. We have found considerable interest and support in seeing these capabilities reach the market. We have previously indicated that we are in discussions with biomedical device companies, with some of these discussions in advanced stages of negotiation. This patent is an important component of the evolving industry interest."
U.S. Patent No. 6,765,144 was issued to Nanoset, LLC, a technology supplier to Biophan, with Biophan holding the worldwide exclusive rights to all medical applications. Biophan and Nanoset worked jointly on the innovation, based on earlier nanotechnology patents developed by Nanoset. A copy of the patent can be viewed on the Company's website at http://www.biophan.com/intellectual.php.
A graphical illustration of the potential use of this technology can be viewed at http://www.biophan.com/mriguided1.php.
About Nanoset, LLC
Nanoset, LLC, based in East Rochester, NY, develops nanomagnetic particle coatings. Nanoset's research and development has been conducted with Alfred University, a world leader in ceramics and thin-film coatings. Nanoset and Biophan are jointly developing technologies for the medical device industry.
About Biophan Technologies
Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 16 issued U.S. patents and 60 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.
Catfish if Justin Timberlake is wearing True Religion jeans then you can bet thousands of teenagers are going to be buying them....I'm on my way to get a pair right now, lol! :)
TRLG: I saw the CEO of TRLG on the "E! Network" because Justin Timberlake wears TRLG jeans. No!!! I don't watch E Networks, the wife does. Previously I had asked her if she ever heard of True Religion jeans....so she brought my attention to the telivision when she heard True Religion mentioned on one of those silly tennie bopper shows the have on E!.
I don't care what Justin Timberlake wears; but I realize that's the socienty we live in.
I can't believe my wife watches that garbage....I listen to jazz...I despise the MTV culture for degenerating the music of this country....and she is an acomplice to this emerging degenerate culture...ugh!
Anywho, TRLG has a trend-setter wearing their brand.
I like the Buddha logo.
What happened to The Microcap Kitchen here and at SI? Is everyone hiding in their cash bunkers?
EKCS taking off today. Already 20 times average volume on no news....could this just be a anti-terror rally...or something more? I'm holding mine.....I'm not seing the other anti-terror stocks making this kind of move?
Maybe that IBDSS contract is finally going to be funded?
MYMX just filed an awesome 8k!!! I thought something had to be brewing. By the way, notice how cheap the company is, they didn't issue a PR to save their limited working capital. A long shot, not a scam.
ITEM 5. OTHER EVENTS.
WORLD PREMIERE: A PROTOTYPE AIDS VACCINE CANDIDATE HAS PRODUCED NEUTRALIZINGANTIBODIES AGAINST PRIMARY STRAINS OF THE HIV-AIDS VIRUS.
The first two (non optimized) variants of our cheaply scaleable, stable andmutated soluble trimeric forms of the gp41 transmembrane protein (the productionof which was announced as a major breakthrough in our filing 8-K dated April 16,2004) have been inoculated to 38 germ-free rabbits over a 4-month period in viewto determine 1) whether such injections are triggering the production ofantibodies, and 2) if yes, whether the resulting antibodies are in fact capableof neutralizing primary strains of HIV, the virus responsible for AIDS.
Primary HIV strains are obtained from HIV+ infected patients and are known to bemuch more resistant to neutralization than so-called laboratory strains, againstwhich certain groups have already obtained neutralizing antibodies, which laterturned out to be of no effect against primary strains.
Our work has demonstrated that both (non-optimized) variants of our mutatedproteins are:
1. strongly antigenic;
2. very stable in the presence of vaccine adjuvants previously approved by theFDA;
3. inducing seric antibodies which have a 50% or more neutralizing activity onearly transmitted (CCR5 tropic) primary strains of HIV (transcytosis test,mimicking mucosal transmission, the major mode of infection).
The latter test has been performed (and twice repeated) by our partner, Dr.Morgane Bomsel, principal investigator at the French National Research Institute(CNRS), at her facilities at the Cochin Institute in Paris (France). Dr. Bomseland her team have been working on mucosal transmission of HIV (and HIVtranscytosis) and mucosal immunity aspects of AIDS since 1995. Since that date,several groups active in this field all over the world have spent a great amountof time and effort in the pursuit of the evasive primary neutralizing antibody,with no positive response until Dr. Bomsel recently tested our antibodies.
Further tests are being conducted by other groups in France and the UnitedStates in order to determine the breadth and depth of our discovery, which webelieve is adequately protected by several US and foreign patents and patentapplications.
Together with our strategic partner Protein' eXpert SA in Grenoble (France), aspin off of the French Nuclear Energy Agency ("Commissariat a l'energieatomique", CEA), we have launched the production of other variations of ourrecombinant stable trimeric gp41 in view of optimizing (and hopefully improvingon) our results. Due to the complexity of the matter, it is likely that morerounds of optimization will be required before the prototype vaccine can besubmitted to human clinical trials, which we do not expect to start before June2005.
Neutralizing antibodies are now accepted as a prime vaccine candidate by amajority of the scientific teams working on AIDS: this is why IAVI(International AIDS Vaccine Initiative, initially funded by the Bill and MelindaGates Foundation) has decided two years ago to concentrate its scientific andfinancial efforts on such antibodies and has consequently fostered theNeutralizing Antibodies Consortium (NAC), which coordinates the work ofprestigious research centers such as the Scripps Institute in San Diego,California, and private companies such as Virologic Inc. in San Francisco,California.
In a nutshell and despite not being a member of the NAC, MYMETICS HAS PRODUCED AFIRST EFFECTIVE YET NOT OPTIMIZED PROTOTYPE OF A PREVENTIVE AND POSSIBLYUNIVERSAL VACCINE AGAINST AIDS WHICH IS STABLE AND COULD BE MASS PRODUCED ATSMALL COSTS.
These encouraging results will be formally presented starting this comingSeptember to two major pharmaceutical companies active on the HIV-AIDS vaccinefront in anticipation of signing a partnership agreement. Experience tellshowever that encouraging results are no guarantee for the actual conclusion ofsuch partnership agreements and that concluding such agreements usually requiresseveral months.
We are still facing serious short term challenges, principally a shortage ofworking capital, that limits our ability to make greater progress in achievingour business plan.
ABOUT Mymetics
Mymetics Corporation is a Delaware registered biotech company operatingprimarily out of France and Switzerland and presently active in the research anddevelopment of preventive vaccines and therapies against AIDS, starting from afundamental discovery made by its founder in 1997 about the HIV virus(responsible for AIDS) and the way it disrupts the patient's immune system.
The company was founded in France under the name Hippocampe SA in 1990. In theyear 2000, it went through a reverse merger with ICHOR Corporation, a dormant UScompany previously listed on the NASDAQ that had sold essentially all of itsassets. The resulting company, the name of which was later changed to MymeticsCorporation, is currently listed on the OTCBB (trading symbol MYMX).
FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements that involve risks anduncertainties. The statements contained in this report that are not purelyhistorical are forward-looking statements within the meaning of Section 21E ofthe Securities Exchange Act of 1934, as amended, and Section 27A of theSecurities Act of 1933, as amended. These forward looking statements concernmatters that involve risks and uncertainties that could cause actual results todiffer materially from those stated in the forward-looking statements. Wordssuch as "may," "will," "should," "could," "expect," "plan," "anticipate,""believe," "estimate," "predict," "potential", "continue", "possibly" or"clearly" or similar words are intended to identify forward looking statements,although not all forward looking statements contain these words.
Although we believe that the expectations reflected in the forward-lookingstatements are reasonable, we cannot guarantee future results, levels ofactivity performance or achievements, nor can we guarantee that our prototypevaccines will be proved effective under human clinical trials conditions.Moreover, neither we nor any other person assumes responsibility for theaccuracy and completeness of the forward-looking statements. We are under noduty to update any of the forward-looking statements after the date hereof toconform such statements to actual results or to changes in our expectations.
Readers are urged to carefully review and consider the various disclosures madeby us which attempt to advise interested parties of the factors which affect ourbusiness, including without limitation disclosures made under the captions"Management Discussion and Analysis of Financial Condition and Results ofOperations," "Risk Factors," "Consolidated Financial Statements" and "Notes toConsolidated Financial Statements" included in the Company's annual report onForm 10-K for the year ended December 31, 2003 and in our Registration Statementon Form S-1 dated May 22, 2002, as amended.
Betababe I'm not ksuave. I used to be No_Hype at RagingBull a few years back....and knew you from the ACCR board. I'm now zenvesting at RagingBull.
MYMX doesn't have any revenue or contracts. They do have some key aspects of a good speculative play (highly credentialed directors and credible partners). They also don't have any floorless convertible debuntures or fishy financing arangements that would make me consider them a scam. I think it's a legitimate long-shot with potential huge returns. I only have a small position....I certainly wouldn't reccomend it as a core holding. But if only one of the long-shots ends up being a 10-bagger, then you can cover a few mistakes you make along the way too.
They only have 80,000,000 authorized shares.....so their fully dilluted market cap is about 8M right now. They have a unique, patented protien that binds to the HIV receptor site, which could be used for HIV therapy and/or vaccines. If they can land a liscensing deal with a major pharma company, I think they could easily double from here....or a lot more.
My portfolio is a mix of value plays and small positions in these kinds of long-shots.
Good luck to you.
Cybercall/Betababe
Great statement:
"I havent looked at it yet but it just sounds like an textbook scam."
Profound Betababe....very deep DD. Why don't you just try to understanding what you're talking about before you make such a statement?
Here's the laboratory that conducted the experiment to validate the mimacy of MYMX's gp41 protien:
http://www.proteinexpert.com/about_us/jdc_about.php
You can see this laboratory is involved with a lot of scams like Pfiezer, Merck, Sanofi-Synthelabo, etc..
The new director, Mr. Jack Francois Martin, looks like a real scammer too....his work with NATO and UNICEF really make him questionable to me, lol:
http://www.unicef.org/mozambique/latest_news_17Out03_09.htm
You're not going to find good opportunites if you just throw baseless judgements around like that.
Catfish GPG brought MYMX to my attention in April when they announced possitive test results for their HIV antisense drug. According to their filings, discussions with two major pharma companies were pending those results.
That drop in August of '02 probably closely corresponds to a former due date for their debt? They've manged to negotiate this repayment out to January '05. now. The two largest shareholders have also ousted the BOD since then and taken over the opperations. They minimized their opperations and have been running the company on fumes since then. They've also appointed some high-profile members to their BOD since then.
So they made some significant accomplishments in the past few months. They successfully tested their HIV antisense drug. According to their filings, negotiations with two major pharma companies were pending those results. They've also gotten private placement investors.
If what their filings say is true, they should be close to getting a deal signed soon?
The Raging Bull board is actually full of good information posted by "hudsuckr".
MYMX at 6 times average daily volume in the first 4 minutes this morning. There's some good DD on the Raging Bull MYMX board posted by "hudsukr".
The company has an HIV antibody and is in discussions with major pharma companies.
ALMI- Heavy volume on no news....I'm not in yet....but it looks pretty compelling here?
BIPH: The CEO said during the shareholder meeting last week they are in the proccess of the first tranches of their financing with SBI Brightline. That coupled with the Boston Scientific recall news after the close Friday....and a weak market sentiment in general resulted in panic selling today IMO.
BUT the BSX news was about the balloons in their stent delivery system and had nothing to do with the coatings (which BIPH is developing next generation coatings with BSX).
Go to this link and look at the presentation titled "Drug Delivery Technologies":
http://www.biophan.com/2004.php
If you got it at .61/.62 congratulations!
I'm still holding all of mine from $0.40....and I really think I'll have a 10-bagger in a year or two.
Good luck!
Stu, I'm not sure what you are reffering to about Gary's I-hub site? Do you mean the Silicoln Investor board:
http://www.siliconinvestor.com/stocktalk/subject.gsp?subjectid=50570
Catfish I e-mailed VRDM IR and got a response indicating the acquisition was completed @ $0.65/share. I don't understand why he wouldn't jus buy on the open market @ $0.28...or whatever? Wierd....like I said...these environmental people can be damn goofy.
Betababe we don't discuss polotics unless the discussion pertains to stocks in some way.
Furthermore, the article you posted about Kerry promoting a political agenda isn't nearly as compelling to me as the documentry Ferenheit 911. Hundereds of American soldiers killed, tens of thousands of innocent Iraqi's, and still no weapons of mass destruction in Iraq. I believe the only success of this war was creating a whole new generation of terrorists....in the children who have us to blame for their parents deaths.
I'm off polotics now.
I'm in defense stocks now because we're in the Bush economy. As fall approaches I'll be looking into some alternative energy stocks for a hedge if Kerry wins.
I don't know if a buyout would be in the cards; but I know there's been a hint about a minority investment from a partner in the June 16th press release:
"In order to have the option to utilize the complete SBI financing, and/or the potential sell equity to one or more strategic partners with whom Biophan is in discussions, the Company will present to its shareholders the approval to authorize additional shares."
I think a minority investment from BSX is more likely than a buy out. I think Biophan could liscense its technology to a wider range of medical device companies as a stand alone business. Where as if BSX owned the technology, they would probably want to keep it exclusive.
Catfish they're available at the SEC website:
http://www.sec.gov/cgi-bin/browse-edgar?company=Veridium&CIK=&filenum=&State=&SIC=&a...
VRDM question??? There was a Form 4 today; but the way I read it, the President/CEO purchased 260k shares today at $0.65???
Am I on misreading this some how....or did he really buy shares at 2x the price on the open market? Or does the form reffer to pre-split shares? Confusing?
I'm an environmental scientist, we can be a bit goofy at times, but is this guy outright dumb?
Stuart re: BIPH,
I hope I'm not being to liberal in connecting these dots; but it sure is interesting that Biophan/Nanoset just discovered (and patented) how their nanomagnetic coatings have drug-eluting properties, while doing R&D with Boston Scientific, who has 75% market share in drug-eluting stents.
Even more interesting to me is that they presented this information during a panel discussion with ANPI today, who is BSXs current liscensor of the drug-eluting tech. for the Taxus stent. If nothing else, the joint-presentation with ANPI at least validates BIPHs claims. But I really think BIPH and ANPI might have a bit more of a relationship/colaboration under the veil of BSX non-disclosure agreements.
I don't know why the market didn't get a little more excited about it; but I sure am.
I'll stop chearleading for now.....and wait patiently for the day when the BSX R&D becomes more transparent.
Good luck!
BIPH news! The correlation with ANPI keeps becoming more apparent, if the current Boston Scientific tests are successful, I believe we'll get much meatier details than we got today:
Biophan CEO to Present at the SRI Institute's Medical Device Investor and Corporate Development Conference
Tuesday June 29, 8:01 am ET
Conference to Focus on Convergence of Drugs, IT, and Medical Devices;
ROCHESTER, N.Y--(BUSINESS WIRE)--June 29, 2004-- Investors' Insights on Future Opportunities in the Medical Device
Industry
Biophan Technologies, Inc. (OTCBB: BIPH - News) an innovator, developer and marketer of MRI-related and other advanced biomedical technology, announced today that the Company's CEO, Michael Weiner, will be a presenter and panel participant at the Strategic Research Institute's Medical Device Investor and Corporate Development Conference today at the Hyatt Regency Princeton in Princeton, NJ. The panel will specifically discuss the growing convergence of medical devices, drugs, and information technology. Joining Mr. Weiner on the panel are Jeanne M. Bertonis, Chief Business Officer of Angiotech Pharmaceuticals, Inc., a $1.6 billion market cap manufacturer of drug-coated medical devices and drug-loaded surgical implants, and Astro Teller, CEO of BodyMedia.
Mr. Weiner will cover some recent advances developed by Biophan's technology partner, Nanoset, LLC, which has recently filed several new patents regarding the use of nanomagnetic particles to enhance the uptake and release of drugs in medical device coatings. Under the expanded relationship between Nanoset and Biophan, announced earlier this year, the Company has exclusive rights to all applications developed by Nanoset in the field of medical devices.
Specific topics that Mr. Weiner will highlight include:
Generating power from body heat using thin-film coating for diagnostics and therapeutics
Coatings for allowing post-implant drug uptake and release
Controllable recharging of drugs in coatings
Controllable drug elution (release)
Detection and treatment of plaque, inflammation, and infection
Broad diagnostics and therapeutics
Coating nanoparticles for use as contrast agents, thus allowing multiple markers in single procedures
Commenting on his presentation, Mr. Weiner stated, "While we have previously announced our initiatives in biothermal power sources and contrast agents, today we are publicly announcing for the first time that, through Nanoset, we are involved in the development of drug elution technologies."
About Biophan Technologies
Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have nine issued U.S. patents and over fifty patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, photonics, and a long-life power source for use in implanted medical devices. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.
About the Strategic Research Institute
The Strategic Research Institute creates, produces and manages conferences covering industry specific business-to-business topics. Its globally recognized events provide powerful business research, education and information, which relates directly to market trends, global competition and technological change.
These conferences also provide a forum for face-to-face networking between industry leaders, potential strategic partners, prospects and customers. The subject matter, target audience, and market acceptance of each Strategic Research Institute conference is thoroughly researched by a team of experts. This ensures that the most pertinent information will be disseminated to the appropriate audience.
Catfish, maybe she was scouting out a board to discuss China stocks?
She posted this earlier on RB, which I find a little extremist, which coming from me means she must be a lunatic :)
http://ragingbull.lycos.com/mboard/boards.cgi?board=CLB01214&read=10433
I've known of the Betababe since 2001, when we used to commiserate over our POS stock....ACCR.
GPG has helped me almost completely recover from some terrible mistakes I made then...like averaging down on ACCR all the way to a 99% loss....hard lessons to learn......THANK GOODNESS.....and GPG.
Insiders selling a little bit, but in a slow and controlled way.
Warren Ruderman sold about 190k of his 1.4M shares. Just looks like a little profit taking at this point.
http://www.sec.gov/cgi-bin/browse-edgar?company=Inrad&CIK=&filenum=&State=&SIC=&...
Stuart,
POSC is the only small PET manufacturer I have seen. But they sold their software to GE Medical Systems last year and that was the one thing that gave them an advantage over the big players.
I'm not sure what a good short-term entry point will be. I would probably buy if it dipped back bellow $0.07; but I'm not sure if it will get back down there again?
POSC I still own it from 2 years ago at $0.07 (it's a tiny position). I didn't buy more recently because I didn't like the fact the financing was done pretty cheap at about $0.024/share. If all the financing is executed it will bring the share count to approximately 150M OS.
But on the possitive side, the company will also be selling 10 systems for $1.3million each, which should give them about $0.11 in revenue/share for these 10 sales. Having an investment from a burgeoning PET service provider is also a big possitive IMO. I'll continue to watch and look for a good entry.
I think the recent volume might possibly be related to this, which is a possitive for the PET industry in general:
KNOXVILLE, Tenn., June 16 /PRNewswire-FirstCall/ -- CTI Molecular Imaging, Inc. (Nasdaq: CTMI), a leading provider of positron emission tomography (PET) equipment, molecular biomarkers and services, commented on yesterday's announcement by the Centers for Medicare and Medicaid Services (CMS) regarding Medicare coverage for the use of PET for early diagnosis of Alzheimer's disease.
CMS has announced a national coverage decision to provide Medicare coverage of PET scans to aid physicians in the early diagnosis of Alzheimer's disease and to help differentiate Alzheimer's from other confounding neurological disorders. The coverage decision would authorize Medicare payment for PET scans when certain criteria are met as outlined in the coverage document. This coverage decision is open to public comment for 30 days, followed by implementation in its final form within the next 60 days. Further information is available at http://www.cms.hhs.gov .
Ronald Nutt, Ph.D., President and Chief Executive Officer, commented on the announcement, "CMS has recognized the significant benefit that PET can provide in the diagnosis of patients suspected of having Alzheimer's disease. PET will provide the opportunity for earlier diagnosis, care and treatment of Alzheimer's patients, while also helping to better manage the overall resources applied to care of patients with Alzheimer's disease and associated disorders. We believe that this coverage decision will help to alleviate the anxiety and uncertainty experienced by Alzheimer's patients and their families."
About CTI Molecular Imaging:
CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, neurological disorders and cardiac disease. Additional information is available at: www.ctimi.com .
About PET and PET/CT:
PET images the biology of diseases at the molecular level, often before changes are visible by anatomical imaging or, in some cases, before symptoms appear. Diseases are biological processes and it is these processes that PET examines. PET/CT combines the biological examination of patients by PET with CT images of the body's structural detail. PET/CT technology improves the diagnostic accuracy and treatment management of patients by providing surgeons, radiation oncologists and other physicians precise anatomical landmarks associated with the disease condition as determined by PET.
PET's whole-body imaging capability helps physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed. Recent published clinical trials have shown that in a wide array of cancers, the use of PET has caused the treatment to be changed for 15 to 50% of patients, depending on the specific clinical question. In addition, PET and PET/CT provide both the patient and their physician with a degree of certainty that is often unavailable through other imaging methods.
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward- looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements.
CTI undertakes no obligation to update or revise any forward-looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. SOURCE CTI Molecular Imaging, Inc.